Opinion|Videos|July 22, 2024

Recent Data on Bimekizumab for Hidradenitis Suppurativa

Vivian Shi, MD, FAAD, reviews recent phase 3 data on bimekizumab, a biologic therapy for patients with hidradenitis suppurativa.

Video content above is prompted by the following:

  • Bimekizumab is a biologic under investigation for hidradenitis suppurativa (HS). What did recent phase 3 results demonstrate?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo